Nancy Index for Ulcerative Colitis Biopsies Explained

The Nancy Histological Index grades microscopic activity in ulcerative colitis biopsy samples. A pathologist assigns one of five grades, from 0 through 4, using the most severe feature present. The index does not include symptoms, CRP, fecal calprotectin, or the colonoscopy’s visible appearance. A person can therefore feel well and have an improved endoscopic score while a biopsy still shows microscopic activity. Histology is a complementary layer, not a replacement for the other layers of UC monitoring (ECCO histology overview; histopathology consensus).

What grades 0 through 4 mean

Grade 0 means no significant histological disease activity. Grade 1 reflects chronic inflammatory infiltrate without acute activity. Grade 2 indicates mild acute activity with neutrophils infiltrating the epithelium. Grade 3 represents moderate or severe acute activity. Grade 4 adds ulceration. Because the highest relevant feature determines the grade, Nancy is simpler than systems that sum many separately weighted microscopic findings (Nancy development reference).

The word “chronic” in a pathology report does not necessarily mean an active flare. Chronic architectural changes and chronic inflammatory cells can persist as evidence of longstanding disease. Acute activity is signaled particularly by neutrophils, cryptitis, crypt abscesses, erosion, or ulceration. Ask whether the reported grade applies to the worst biopsy, a particular segment, or an overall summary.

Sampling matters. Biopsies are tiny and inflammation can vary across the colon. The number and location of samples, treatment exposure, tissue orientation, and reader interpretation affect the result. A Nancy 0 from sampled sites cannot guarantee that every area of the colon is microscopically normal.

Nancy versus Geboes and Robarts

The Geboes score is a more detailed hierarchical grading system. The Robarts Histopathology Index, or RHI, combines four weighted items into a continuous score. Nancy uses five ordinal grades and is often easier to apply. These values cannot be converted directly because the instruments organize and weight findings differently (ECCO histology overview; ECCO reporting review).

Consensus documents commonly recognize Nancy and RHI as validated UC histology indices, while Geboes remains widely used. The score name and definition of histologic remission must be included when reading a study result (histopathology consensus).

For serial comparisons, the same index and sampling approach provide the clearest trend.

Where labs and endoscopy fit

CRP and calprotectin do not enter Nancy. Calprotectin may correlate with neutrophilic activity at a group level, but an individual result can disagree because the tests sample different things at different times. The Mayo Endoscopic Subscore or UCEIS grades what is seen during the scope, while Nancy grades what is seen microscopically in tissue.

STRIDE-II treats histologic healing in UC as a measure of depth of remission rather than a formal treatment target by itself (STRIDE-II). Do not change medication from a biopsy grade alone. Keep the grade, segment, pathology wording, biopsy date, endoscopic score, preparation quality, medication exposure, symptoms, CRP, and calprotectin together. The value of Nancy is not that it declares the whole disease “good” or “bad.” It makes microscopic inflammatory activity concise enough to compare and discuss.

Questions that make the number more useful

Before comparing this result with an older one, confirm that both records used the same named instrument, version, scoring range, and assessment window. Ask whether the total represents the worst segment, a sum across segments, an average, or a single day. If a clinician or study used a modified version, record exactly what was removed or added. Also check whether treatment, bowel preparation, infection, missed diary entries, or incomplete examination affected the inputs. A small apparent change may reflect measurement conditions rather than a meaningful change in disease.

At a visit, useful questions include: What domain does this score measure? Which component drove the result? What would count as response or remission in this setting? Does the number need confirmation with blood work, stool testing, endoscopy, biopsy, or imaging? Is the goal to follow symptoms, current inflammation, structural damage, treatment response, or quality of life? Asking these questions turns an unfamiliar total into a specific clinical conversation.

For personal tracking, avoid combining unlike scores on one graph. Keep each instrument in its own series and place objective tests on parallel timelines. Save the source report because the component details may matter later. Note both the sample or procedure date and the date you received the result. Trends are easiest to interpret when the method and timing stay consistent. If the number conflicts with how you feel or with another test, bring the disagreement to your care team instead of choosing the result that seems most reassuring. Discordance is often the reason to look more closely.